These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 1451721)

  • 1. Steady-state plasma levels of clomipramine and its metabolites: impact of the sparteine/debrisoquine oxidation polymorphism. Danish University Antidepressant Group.
    Nielsen KK; Brøsen K; Gram LF
    Eur J Clin Pharmacol; 1992; 43(4):405-11. PubMed ID: 1451721
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Steady-state concentrations of imipramine and its metabolites in relation to the sparteine/debrisoquine polymorphism.
    Brøsen K; Klysner R; Gram LF; Otton SV; Bech P; Bertilsson L
    Eur J Clin Pharmacol; 1986; 30(6):679-84. PubMed ID: 3533565
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma steady-state concentrations of hydroxylated metabolites of clomipramine.
    Linnoila M; Insel T; Kilts C; Potter WZ; Murphy DL
    Clin Pharmacol Ther; 1982 Aug; 32(2):208-11. PubMed ID: 7094507
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single-dose kinetics of clomipramine: relationship to the sparteine and S-mephenytoin oxidation polymorphisms.
    Nielsen KK; Brøsen K; Hansen MG; Gram LF
    Clin Pharmacol Ther; 1994 May; 55(5):518-27. PubMed ID: 8181196
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clomipramine dose-effect study in patients with depression: clinical end points and pharmacokinetics. Danish University Antidepressant Group (DUAG).
    Clin Pharmacol Ther; 1999 Aug; 66(2):152-65. PubMed ID: 10460069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Moclobemide treatment causes a substantial rise in the sparteine metabolic ratio. Danish University Antidepressant Group.
    Gram LF; Brøsen K
    Br J Clin Pharmacol; 1993 Jun; 35(6):649-52. PubMed ID: 8329293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma concentration of clomipramine and desmethylclomipramine and clinical response in depressed patients.
    Montgomery SA; McAuley R; Montgomery DB; Dawling S; Braithwaite RA
    Postgrad Med J; 1980; 56 Suppl 1():130-3. PubMed ID: 7393823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The metabolism of mexiletine in relation to the debrisoquine/sparteine-type polymorphism of drug oxidation.
    Broly F; Vandamme N; Libersa C; Lhermitte M
    Br J Clin Pharmacol; 1991 Oct; 32(4):459-66. PubMed ID: 1958440
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Importance of oxidative polymorphism and levomepromazine treatment on the steady-state blood concentrations of clomipramine and its major metabolites.
    Balant-Gorgia AE; Balant LP; Genet C; Dayer P; Aeschlimann JM; Garrone G
    Eur J Clin Pharmacol; 1986; 31(4):449-55. PubMed ID: 2880723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High plasma concentrations of desmethylclomipramine after chronic administration of clomipramine to a poor metabolizer.
    Balant-Gorgia AE; Balant L; Zysset T
    Eur J Clin Pharmacol; 1987; 32(1):101-2. PubMed ID: 3582462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population.
    Broly F; Gaedigk A; Heim M; Eichelbaum M; Morike K; Meyer UA
    DNA Cell Biol; 1991 Oct; 10(8):545-58. PubMed ID: 1681816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enzymatic basis of the debrisoquine/sparteine-type genetic polymorphism of drug oxidation. Characterization of bufuralol 1'-hydroxylation in liver microsomes of in vivo phenotyped carriers of the genetic deficiency.
    Dayer P; Kronbach T; Eichelbaum M; Meyer UA
    Biochem Pharmacol; 1987 Dec; 36(23):4145-52. PubMed ID: 3689440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma concentrations of clomipramine and desmethylclomipramine in obsessive-compulsive neurosis.
    Luscombe DK; Wright J; Stern RS; Mawson D; Marks IM
    Postgrad Med J; 1980; 56 Suppl 1():140-3. PubMed ID: 7393825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Variation in plasma concentrations of clomipramine and desmethylclomipramine during clomipramine therapy.
    Hullin RP
    Postgrad Med J; 1980; 56 Suppl 1():117-9. PubMed ID: 7190279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The biotransformation of clomipramine in vitro, identification of the cytochrome P450s responsible for the separate metabolic pathways.
    Nielsen KK; Flinois JP; Beaune P; Brøsen K
    J Pharmacol Exp Ther; 1996 Jun; 277(3):1659-64. PubMed ID: 8667235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sparteine oxidation polymorphism: a family study.
    Brøsen K; Otton SV; Gram LF
    Br J Clin Pharmacol; 1986 Jun; 21(6):661-7. PubMed ID: 3741716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of clomipramine during pregnancy.
    Ter Horst PG; Proost JH; Smit JP; Vries MT; de Jong-van de Berg LT; Wilffert B
    Eur J Clin Pharmacol; 2015 Dec; 71(12):1493-500. PubMed ID: 26416100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sparteine oxidation polymorphism in Denmark.
    Brøsen K; Otton SV; Gram LF
    Acta Pharmacol Toxicol (Copenh); 1985 Nov; 57(5):357-60. PubMed ID: 4090995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sparteine oxidation polymorphism in Greenlanders living in Denmark.
    Brøsen K
    Br J Clin Pharmacol; 1986 Oct; 22(4):415-9. PubMed ID: 3768256
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Plasma levels of desmethylclomipramine and clomipramine at steady-state in the morning. Correlative analysis and prediction of theoretical blood clomipramine].
    Champiat JC; Aymard N; des Lauriers A
    Encephale; 1983; 9(1):23-36. PubMed ID: 6872932
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.